articleUrologySep 1, 2002Closed access

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

CGClaus G. RoehrbornPBPeter BoyleJCJ. Curtis NickelKJK J HoefnerGLGerald L. Andriole

The University of Texas Southwestern Medical Center · European Institute of Oncology · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

733
total citations
FWCI
42.88
Percentile
100%
References
36
Citations per year

Authors

5

Topics & keywords

Topics
Keywords
  • Medicine
  • Dutasteride
  • Urology
  • Placebo
  • Dihydrotestosterone
  • Hyperplasia
  • Prostate
  • 5 Alpha-Reductase Inhibitor
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.